Learn about our latest developments!
Keep up to date with our latest news, acquisitions, product launches & business news here.
Celltrion Healthcare Australia (Celltrion) and Juno Pharmaceuticals (Juno) have entered in to a co-marketing partnership, covering the biosimilar products Herzuma (biosimilar trastuzumab), and Truxima (biosimilar rituximab).
Juno Pharmaceuticals is pleased to announce the acquisition of noradrenaline 2 mg/2 mL and 4 mg/4 mL concentrated injection from Mayne Pharma; an important addition to Juno’s growing range of vasopressors and critical care medicines.
Juno Pharmaceuticals Pty Ltd is pleased to announce the acquisition of a local portfolio of essential injectable medicines from AstraZeneca Pty Ltd.